MoonLake Immunotherapeutics (MLTX) EBT (2021 - 2026)

MoonLake Immunotherapeutics' EBT history runs 6 years deep, the most recent figure standing at -$69.1 million for Q1 2026.

• In Q1 2026, EBT fell 70.98% year-over-year to -$69.1 million; the TTM figure through Mar 2026 stood at -$258.4 million (down 75.22% YoY), while the FY2025 annual figure was -$229.7 million, down 89.9% from the prior year.
• EBT was -$69.1 million for Q1 2026 at MoonLake Immunotherapeutics, down from -$62.8 million in the prior quarter.
• In the past five years, EBT ranged from a high of -$7.8 million in Q4 2023 to a low of -$70.6 million in Q3 2025.
• Historically, EBT has averaged -$31.1 million across 5 years, with a median of -$17.4 million in 2022.
• Biggest YoY gain for EBT was 69.32% in 2022; the steepest drop was 20705.61% in 2022.
• A 5-year view of EBT shows it stood at -$16.5 million in 2022, then soared by 52.34% to -$7.8 million in 2023, then tumbled by 491.0% to -$46.4 million in 2024, then slumped by 35.41% to -$62.8 million in 2025, then retreated by 10.06% to -$69.1 million in 2026.
• The last three EBT figures came in at -$69.1 million (Q1 2026), -$62.8 million (Q4 2025), and -$70.6 million (Q3 2025), per Business Quant data.